Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences.
about
Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.Negative affective states and cognitive impairments in nicotine dependencePredictors of smoking severity in patients with schizophrenia and alcohol use disorders.The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia?Risky use of alcohol, drugs and cigarettes in a psychosis unit: a 1 1/2 year follow-up of stability and changes after initial screening.European network for promoting the physical health of residents in psychiatric and social care facilities (HELPS): background, aims and methodsRate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis.Friends and symptom dimensions in patients with psychosis: a pooled analysis.The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.Prevalence and socio-demographic risk factors associated with psychoactive substance use in psychiatric out-patients of a tertiary hospital in Nigeria.Simultaneous alcohol and cannabis expectancies predict simultaneous use.A comparative study of reliability of self report of tobacco use among patients with bipolar and somatoform disordersAlcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia.The impact of substance use on brain structure in people at high risk of developing schizophrenia.Screening for substance use disorders in first-episode psychosis: implications for readmission.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patientsDrug and alcohol misuse in first episode psychosis: An observational study.Test-retest reliability of self-report measures in a dually diagnosed sampleCigarette Smoking and Health Characteristics in Individuals With Serious Mental Illness Enrolled in a Behavioral Weight Loss Trial.Development of psychotic symptoms following ingestion of small quantities of alcoholPrevalence of Substance Use in Patients Diagnosed with Schizophrenia.Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis.Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use.Comorbid addiction and major mental illness in Europe: a narrative review.Opiate dependence in schizophrenia: case presentation and literature review.Pharmacological treatment of schizophrenia with comorbid substance use disorder.Recreational alcohol use induces changes in the concentrations of choline-containing compounds and total creatine in the brain: a (1)H MRS study of healthy subjects.Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder.Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia.Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample.Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction.Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study.Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic reviewSafety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients.Comorbidity of Axis I and II mental disorders with schizophrenia and psychotic disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.Substance use disorders among psychotic patients admitted to inpatient psychiatric care.Axis IV psychosocial problems among patients with psychotic or mood disorders with a cannabis use disorder comorbidity.Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
P2860
Q30251634-7E521F85-13C4-435E-9BDF-20CC4CA2A288Q30371220-9D665308-588D-4FE2-BC7B-7DEABC27551FQ30463995-23896173-7D83-4030-A15C-47EEE32E42DBQ31149257-D3DFAC70-5382-465A-BD2D-75F76B51F9C7Q33290242-E7E87211-A9A7-4A08-BD41-7FD5207DA377Q33498111-D146260A-7AC8-4A9A-BD77-F7C9E27273AAQ34235419-651384D0-004F-4440-BA11-FD4FBEFFED38Q34491079-9FC17E32-474F-4ECA-BAA0-2F4D16EBB946Q34531537-18F1FF44-C562-49B3-981D-3E41539A8BECQ34675579-C11D1C52-07E7-459F-8676-B52FB4A765AFQ35110603-37D196BB-308C-46D9-96E1-98324F9EC1C6Q35167735-9B5D2F82-7F64-4B42-ADA3-A6690F019604Q35175759-98A22536-5F86-48FB-8628-075670409CF9Q35177137-580D7F76-6F1E-4E2C-AA92-2DD72477A328Q35323897-93065E84-6E54-4E12-B9E0-0412D7F7AA09Q36059843-DC514691-BDC7-4E33-9F54-51B8F03F2620Q36083997-AFB82DA8-A5F2-4157-8E22-5103A8FA3468Q36793655-5B774AF1-5A03-42B8-93A6-DF0A2113BE3DQ36842165-3EDC8505-EBE9-4EB1-A5CC-9D996EB95029Q37183824-52997290-4856-4A12-81CF-CD0EA43915A4Q37190653-1E326CCE-71FC-46AD-BFF1-212E05829AE4Q37283432-43336260-BBEE-417F-BBDB-835306C98007Q37704084-65D59AC2-9D77-4898-AAA3-173AB8E1B262Q38076103-11E5A61F-EC6E-499E-AB5F-1B55BC47697AQ38192896-ACE3A162-C9E1-4FEB-85E0-CDD1D493CABEQ38249235-43A735E3-1099-4A30-9B57-73ADAB0A68A7Q38267760-FE26912A-73FB-4B10-94D5-9C04344D1ED4Q38658672-F11CFEB0-1C4D-414C-8DA7-869A6750E18BQ39006554-BFA4C2BC-8D54-4EBE-A43A-8DE3D81D7D52Q39480548-22A6A052-85C9-4505-A66F-4078F16CC9DCQ40175951-783EC8FC-DBB4-4A29-B435-CB42062C87AAQ40190654-7F0A6D42-CEDA-4CD0-A18E-559EB461DFE1Q40321770-FC3EE34E-E59D-4279-B326-F06C4724B795Q41437823-B82DBDB8-60E6-4917-A9AB-34D42A1C18C1Q41664978-2186AA92-CEB4-4591-AD6E-B2FD31568DF3Q42733571-58EA1B4A-6775-47D7-9C19-51935DAD216AQ43297577-32707E69-B194-4D36-8C79-EF4876DFAD89Q43471662-9A9AEE40-6865-4F9E-AD80-BAB5A7EAFE82Q43487337-9F965F91-79E0-456D-82BE-6ED92E7EB445Q46489466-5A65D477-4989-4DC0-8053-BB5407A9C4A6
P2860
Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Drug and alcohol use among pat ...... oses: levels and consequences.
@en
Drug and alcohol use among pat ...... oses: levels and consequences.
@nl
type
label
Drug and alcohol use among pat ...... oses: levels and consequences.
@en
Drug and alcohol use among pat ...... oses: levels and consequences.
@nl
prefLabel
Drug and alcohol use among pat ...... oses: levels and consequences.
@en
Drug and alcohol use among pat ...... oses: levels and consequences.
@nl
P2093
P921
P1476
Drug and alcohol use among pat ...... oses: levels and consequences.
@en
P2093
Howard C Margolese
Juan Carlos Negrete
Kathryn Gill
Leslie Malchy
Raymond Tempier
P304
P356
10.1016/S0920-9964(02)00523-6
P407
P577
2004-04-01T00:00:00Z